Lucosky Brookman LLP represented Newbridge Securities Corporation, acting as sole book-running manager, in connection with Actuate Therapeutics, Inc.’s (Nasdaq: ACTU) approximately $11 million underwritten public offering of common stock and accompanying warrants.
Actuate Therapeutics, a clinical-stage biopharmaceutical company focused on developing innovative cancer therapies, announced an offering consisting of 30,985,900 shares of common stock and warrants to purchase up to 15,492,950 additional shares of common stock. The securities were offered at a combined public offering price of $0.71 per two shares of common stock and one accompanying warrant, with each warrant carrying an exercise price of $0.45 per share.
The offering was conducted pursuant to an effective shelf registration statement filed with the U.S. Securities and Exchange Commission. Gross proceeds are expected to be approximately $11 million, before deducting underwriting discounts, commissions, and other offering expenses.
Lucosky Brookman LLP served as counsel to Newbridge Securities Corporation in connection with the offering.
